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Background: Inhaled antibacterial agents are used
to manage chronic pulmonary infections in cystic
ﬁbrosis (CF) and non-CF bronchiectasis. However,
established nebulized preparations impose a substan-
tial time burden on patients. A dry powder formula-
tion of ciproﬂoxacin for inhalation (ciproﬂoxacin DPI)
has been developed using PulmoSphere™ (Novartis,
Pharma AG, Basel, Switzerland) technology (adminis-
tered using a T-326 inhaler) to maximize antibacterial
activity and convenience.
Objective: This study investigated the tolerability and
pharmacokinetic properties of multiple-dose once-daily
and twice-daily ciproﬂoxacin DPI in adults with CF.
Methods: A Phase I, randomized, single-blind, pla-
cebo-controlled, dose-escalation study in patients with
CF (median age 29.0 years [19–40]), stable pulmonary
status, and chronic Pseudomonas aeruginosa coloniza-
tion. Sequential cohorts received ciproﬂoxacin DPI
32.5 mg qd (1 capsule for inhalation; n = 6), 65 mg qd
(2 capsules for inhalation; n = 6), or 32.5 mg (n = 6)
bid for 7 days. Each group was placebo controlled.
Results: Twenty-ﬁve patients were enrolled (12 men;
median age, 29.0 years [range, 19–40 years]; 6, 6, 6,
and 7 patients in the ciproﬂoxacin DPI 32.5 mg qd,
65 mg qd, and 32.5 mg bid and placebo groups,
respectively). No serious treatment-emergent adverse
events or clinically relevant changes in tolerability
parameters, including lung function measurements,
were reported. Twenty-one patients (ciproﬂoxacin,
n ¼ 17; placebo, n ¼ 4) experienced 29 mild drug-
related treatment-emergent adverse events, including
bitter taste (ciproﬂoxacin, 17 patients; placebo, 2) and
bronchospasm (ciproﬂoxacin, 3; placebo, 2). Ciproﬂox-
acin DPI was absorbed rapidly after inhalation.October 2013Systemic exposure to ciproﬂoxacin was low and com-
parable between single and multiple dosing in all 3
dose groups, suggesting an absence of substantial drug
accumulation. The geometric mean AUCs after the last
dose were 0.383, 1.472, and 0.781 mg  h/L with
ciproﬂoxacin DPI 32.5 mg qd, 65 mg qd, and 32.5 mg
bid, respectively. The range of geometric mean t½ in
plasma was 3.4 to 9.5 hours. Sputum concentrations
of ciproﬂoxacin were high, with substantial variability.
Geometric mean ciproﬂoxacin concentrations (%CV)
in induced sputum were 57.7 (118.2), 177.5 (53.4),
and 149.7 (249.7) mg/L 0.75 hours after the last dose
of ciproﬂoxacin DPI 32.5 mg qd, 65 mg qd, and 32.5
mg bid, respectively.
Conclusions: Ciproﬂoxacin DPI was well tolerated,
especially with respect to lung function, with minimal
systemic exposure compared with data from previous
studies of oral and intravenous administration, and
with no apparent accumulation at steady state. Sputum
ciproﬂoxacin concentrations above 100-times the mini-
mum inhibitory concentration for P aeruginosa were
detected. Ciproﬂoxacin DPI may be effectively delivered
to the lungs at microbiologically active concentrations
while minimizing the risk for systemic intolerabilities.
Eudra clinical trial identiﬁer: 2006-003690-26. (Clin
Ther. 2013;35:1571–1581)1571
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Chronic pulmonary infection and inﬂammation can
lead to progressive lung damage, which can ultimately
result in respiratory failure, and both are key charac-
teristics of lung diseases such as cystic ﬁbrosis (CF) or
non-CF bronchiectasis.1–3 Pseudomonas aeruginosa is
a frequently encountered respiratory pathogen asso-
ciated with chronic infection in CF and in other
respiratory diseases.4,5
Patients chronically infected with P aeruginosa expe-
rience periodic pulmonary exacerbations that can lead to
irreversible loss of lung function despite treatment with
antibacterial agents.6 The frequency of pulmonary
exacerbation is strongly associated with the progressive
decline in lung function,3,7 and both negatively affect
patients’ quality of life.8,9 The use of inhaled antipseu-
domonal antibiotic agents has emerged as an important
strategy for the management of chronic lung infec-
tions.10,11 Aerosolized antibiotics can deliver effective
drug concentrations to the site of infection while
minimizing systemic exposure and the risk for systemic
adverse effects.12 Dry powder inhalers (DPIs) offer the
beneﬁt of rapid administration (use of an inhaler takes
less than a minute,13 whereas use of a nebulizer takes
several minutes14) and reduced setup and cleaning times
compared with nebulizers. These beneﬁts have the
potential to improve patient compliance.15
Oral or intravenous administration of ciproﬂoxa-
cin, a ﬂuoroquinolone with antipseudomonal activ-
ity,16 has been used for the treatment of pulmonary
infections for several years. A DPI formulation of
ciproﬂoxacin,* with an extended residence time in the
lungs (mean residence time/geometric %CV,
10.68 hours/14.8 hours),17 has been developed.18
Ciproﬂoxacin DPI is manufactured with technology†
that uses particles of a controlled size (r5 mm mass
median aerodynamic diameter), with a powder density
and morphology optimized for pulmonary delivery
into the bronchopulmonary system (eg, bronchioles),
because particle size determines deposition site of dry
powder in the respiratory system after inhalation. The*Trademark: Cipro DPI (Bayer Pharma AG, Berlin, Germany).
†Trademark: PulmoSphere™ (Novartis Pharma AG, Basel,
Switzerland).
1572drug is administered using a capsule-based DPI,‡ with
each capsule containing 50 mg of dry powder,
corresponding to 32.5 mg of active ingredient. This
mode of administration allows the deposition of high
concentrations of ciproﬂoxacin to reach the lungs
while keeping systemic drug exposure low (ie, drug
targeting).
In previous Phase I, single-dose studies, ciproﬂoxacin
DPI use was well tolerated and resulted in low systemic
exposure and effective delivery of active drug to the
lungs in healthy volunteers18 and in patients with CF.19
In healthy volunteers, no clinically relevant adverse
events (AEs) and no clinically relevant changes in vital
signs, electrocardiography (ECG) outputs, or lung
function were observed; pharmacokinetic (PK) para-
meters were consistent with low systemic exposure and
effective delivery, with an AUC of 0.354 mg  h/L, a
median Tmax of 0.6 hour, a plasma Cmax of 0.06 mg/L,
a t½ of 9.5 hours, an apparent clearance of 91.7 L/h,
and an apparent volume of distribution of 1262 L.18
Here, we report the results of a Phase I, dose-
escalation study of ciproﬂoxacin DPI. The primary
objective of this study was to evaluate the tolerability
of ciproﬂoxacin DPI treatment administered once or
twice daily in adult patients with CF. The secondary
objective was to investigate the PK properties of cipro-
ﬂoxacin after inhalation, to demonstrate that the ex-
posure in the lungs required for effective treatment of P
aeruginosa infection can be reached in patients with CF.
PATIENTS AND METHODS
Study Patients
Male and female adult patients aged 18 to 60 years
with conﬁrmed CF and colonized with P aeruginosa
were eligible for participation. Additional eligibility
requirements included stable pulmonary status, forced
expiratory volume in 1 second (FEV1) Z30% (range,
30%–80%) of predicted, and a body mass index of 16
to 30 kg/m2. Key exclusion criteria included coloni-
zation of the respiratory tract with Burkholderia
cepacia, acute allergic bronchopulmonary aspergillo-
sis, pulmonary exacerbations, need for lung trans-
plantation, severe liver cirrhosis, massive hemoptysis
in the preceding 4 weeks, febrile illness in the preced-
ing 7 days, smoking habit (420 cigarettes/d), and use
of medication within 3 days before study start that
could have interfered with the investigational drug.‡Trademark: T-326 (Novartis).
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H. Stass et al.All patients provided written, informed consent,
and study approval was obtained from the ethics
committee at the State Ofﬁce of Health and Social
Affairs, Berlin, Germany. The study was conducted in
accordance with the Declaration of Helsinki, the
International Conference on Harmonisation/Good
Clinical Practice guidelines, the European Union
Directive 2001/20/EC, and German drug law
(Arzneimittelgesetz).
Ciprofloxacin DPI Formulation
Ciproﬂoxacin DPI uses the zwitterionic salt cipro-
ﬂoxacin betaine, which has a prolonged t½ compared
with the neutral chemical form of oral ciproﬂoxacin,
ciproﬂoxacin hydrochloride (t½, 13.5 vs o1 hour,
respectively, in preclinical studies), with ciproﬂoxacin
instilled intratracheally as a micronized suspension.20
The formulation incorporates PulmoSphere™ tech-
nology, in which an emulsion-based, spray-drying
process creates ultra-low-density, sponge-like particles
of a controlled size, density, and morphology opti-
mized for pulmonary delivery (o5 μm mass median
aerodynamic diameter).21–23
Study Design and Treatment
This randomized, single-blind, placebo-controlled,
multiple-dose, dose-escalation study (Eudra clinical
trial identiﬁer: 2006-003690-26) was conducted at
the Department of Pediatric Pneumology and Immu-
nology Clinic, Charité, Berlin, Germany.
Eligible patients were randomized (1:3), using a
randomization list set up by the sponsor, to receive
ciproﬂoxacin DPI or placebo for 7 days. Dose escala-
tion was scheduled to proceed with cohorts of
8 patients (ciproﬂoxacin DPI, n = 6; placebo, n = 2),
based on an acceptable beneﬁt–risk assessment per-
formed on the previous dose step (tolerability and PK
assessments were required prior to commencement of
the next step in the escalation scheme). Each group
was placebo controlled and was blinded to study
medication. The study would be terminated if, based
on investigators’ assessments, one of the following
occurred: serious AEs rendering the beneﬁt–risk ratio
unacceptable for this patient population; discontinua-
tions too numerous for the trial to be completed; or
unacceptable risks identiﬁed on interim analyses or in
parallel clinical or animal studies.
Ciproﬂoxacin DPI and matched placebo were given
in identical capsules that were administered afterOctober 2013completion of the patients’ regular CF treatment.
The ﬁrst cohort received an inhaled dose of cipro-
ﬂoxacin DPI 32.5 mg qd (corresponding to
1 capsule containing 50 mg of dry powder). Subsequent
cohorts were administered 2 capsules daily (ciproﬂox-
acin DPI 65 mg qd or ciproﬂoxacin DPI 32.5 mg bid).
The study drug was administered by inhalation on
the morning of day 1 (0 hour) after a fasting period of
Z8 hours (Z4 hours in patients with diabetes). For
twice-daily dosing (ciproﬂoxacin DPI 32.5 mg),
1 capsule was administered on the morning of day 1
(0 hour) after a fasting period of Z4 hours, and
another was administered 12 hours later, after a
fasting period of Z2 hours. On days 2 to 6, there
were no fasting periods before or after inhalation.
Fasting requirements on day 7 were identical to those
on day 1. Immediately after the administration of
ciproﬂoxacin DPI on days 3 to 6, patients in the twice-
daily group rinsed the oral cavity 3 times with 10 to
15 mL of tap water to allow quantiﬁcation of the drug
residing in the oral cavity after the inhalation
maneuver.
Tolerability Assessments
Physical examination, vital signs, clinical chemistry
and hematology, urinalysis, and 12-lead ECG and lung
function tests (thoracic gas volume, speciﬁc total
resistance, and spirometry (FEV1) were carried out at
screening, at scheduled visits throughout the study, and
at follow-up. AEs were assessed throughout the study
using the Medical Dictionary for Regulatory Activities
(MedDRA) version 11.1.
Pharmacokinetic Analysis
For PK analysis in the once-daily dosing groups,
blood samples were obtained from the peripheral
venous system (forearm) before and at 5, 15, 45, 60,
90, 120, and 180 minutes and 3, 4, 6, 8, 12, and
16 hours after dosing on days 1 and 7; predose on
day 6; and at 24, 36, and 48 hours after the ﬁnal dose. In
the twice-daily dosing group, additional samples were
taken at 15, 45, 60, and 90 minutes and 2 and 3 hours
after the second dose on days 1 and 7; at 12 hours
postdose on day 2; and at 12, 24, 36, and 48 hours
after the ﬁnal dose. In addition, 1-hour–postdose
samples were taken on days 3 and 5 in all groups.
Urine samples were collected on days 1 and 7 at 0–4,
4–8, 8–12, 12–24, and 24–48 hours (once-daily
dosing, day 7 only), and then at 12–24 hours after1573
Clinical Therapeuticsdosing on days 3 to 5 (once-daily dosing only).
Induced sputum samples (induced using the method
described by Reinhardt et al24) were collected at the
following times on days 1 and 7: 45 minutes and
5 hours after the ﬁrst inhalation, with an additional
sample taken at 45 minutes after the second inhalation
in the twice-daily dosing group. All plasma and
sputum samples were stored at o–151C and analyzed
within 4 weeks after sampling.
Concentrations of ciproﬂoxacin in plasma, urine,
induced sputum, spontaneous sputum, and oral rins-
ing ﬂuid were determined using a HPLC-MS/MS
method, as described elsewhere.18
PK parameters were calculated using model-inde-
pendent, compartment-free methods with WinNonlin
version 4.1a (Pharsight Corporation, Mountain
View, California). The following PK parameters were
evaluated: AUC during the dosing interval (AUC12
and AUC24); AUC during the dosing interval, nor-
malized to dose and body weight (AUC12,norm and
AUC24,norm); Cmax normalized to dose and body
weight (Cmax,norm), Tmax, elimination rate constant
(λz), t½, amount excreted unchanged in urine (Aeur),
and amount recovered from oral cavity via rinsing
with tap water (Ae). The terminal t½ was determined
by log-linear regression in the elimination phase,
which was established by visual inspection. PK para-
meters were compared between the ﬁrst dose of
ciproﬂoxacin DPI (day 1 [0–24 hours for ciproﬂox-
acin DPI 32.5 and 65 mg qd; 0–12 and 12–24 hours
for ciproﬂoxacin DPI 32.5 mg bid]) and the last
dose of ciproﬂoxacin DPI (day 7 [144–168 hours
for ciproﬂoxacin DPI 32.5 mg and 65 mg qd; 144–
156 and 156–168 hours for ciproﬂoxacin DPI
32.5 mg bid]).
Statistical Analysis
No formal statistical sample size estimation was
performed prior to initiation owing to the exploratory
nature of the study.
All patients who received at least 1 dose of cipro-
ﬂoxacin DPI or placebo were included in the toler-
ability analysis. After thorough assessment of relevant
protocol deviations, all patients who completed the
study were included in the evaluation of PK param-
eters. Statistical evaluation was performed using SAS
version 9.1 (TS1M3) (SAS Institute Inc, Cary, North
Carolina). Data are summarized using descriptive
statistics.1574RESULTS
Patients
Patients were enrolled into the study betweenMay 15,
2007, and January 30, 2008. The safety popula-
tion comprised 25 patients (12 men; median age,
29.0 years [range, 19–40 years]; 6, 6, 6, and 7 patients
in the ciproﬂoxacin DPI 32.5 mg qd, 65 mg qd, and
32.5 mg bid and placebo groups, respectively). One
patient in the placebo group erroneously received
ciproﬂoxacin DPI 65 mg qd; this constituted a proto-
col violation because the study protocol deﬁned
dropout as a patient who discontinued participation
in the trial prematurely for any reason. This patient
was deﬁned as such and replaced in this study. All
18 patients who received ciproﬂoxacin DPI completed
the study and were included in the PK analysis (Figure 1).
The baseline demographic and clinical characteristics
of the study population are shown in Table I.
Tolerability
Overall, 24 patients experienced at least 1 treat-
ment-emergent adverse event (TEAE) (Table II). In
patients receiving ciproﬂoxacin DPI, all TEAEs were
of mild intensity, and those most commonly reported
were bitter taste (n = 17), bronchospasm (9), head-
ache (3), and upper respiratory tract infection (3). One
patient receiving placebo experienced a moderate
TEAE (peripheral neuropathy; considered by the in-
vestigator as not related to study treatment). Twenty-
one patients (ciproﬂoxacin DPI, 17; placebo, 4)
experienced 29 mild, drug-related TEAEs, including
bitter taste (ciproﬂoxacin, 17 patients; placebo, 2 pati-
ents); bronchospasm (ciproﬂoxacin, 3; placebo, 2);
nausea, feeling hot, dizziness, and headache (1 each
with ciproﬂoxacin); and strange powdery taste (1 with
placebo). No deaths or serious or clinically relevant
AEs were reported during the study. No clinically
relevant inﬂuence on blood pressure, heart rate, ECG
parameters (including QT and QT interval corrected
for heart rate using the Bazett or Fridericia formula),
or lung function (thoracic gas volume, speciﬁc total
resistance, and FEV1) was reported after multiple
doses of ciproﬂoxacin DPI.
Pharmacokinetic Properties
The PK properties of ciproﬂoxacin DPI are sum-
marized in Table III. One patient who received the
study medication on the wrong day was excluded
from the PK analysis.Volume 35 Number 10
• 24 patients completed the study
• All patients (n = 25) were included in the tolerability analyses
• 24 patients were included in the PK analyses
Assessed for eligibility (n = 24)
Randomized (n = 24)
Dose step 1:
Ciprofloxacin DPI 32.5 mg qd (n = 6); Placebo (n = 2)
Completed tolerability and PK assessments prior to
dose escalation:
Ciprofloxacin DPI (n = 6); Placebo (n = 2)
Dose step 2: 
Ciprofloxacin DPI 65 mg qd (n = 6); Placebo (n = 3)*
Completed tolerability and PK assessments prior to
dose escalation:
Ciprofloxacin DPI (n = 6); Placebo (n = 2)
Dose step 3:
Ciprofloxacin DPI 32.5 mg bid (n = 6); Placebo (n = 2)
Completed tolerability and PK assessments:
Ciprofloxacin DPI (n = 6); Placebo (n = 2)
Figure 1. Flow of the participants in this study of
the tolerability and pharmacokinetic
properties of ciprofloxacin dry powder
for inhalation (DPI) 32.5 mg qd, 65 mg
qd, and 32.5 mg bid in patients with
cystic fibrosis. *One placebo patient
received ciprofloxacin DPI 65 mg in error.
This patient was regarded as a drop-out
from the study and replaced.
H. Stass et al.After the ﬁrst dose of ciproﬂoxacin DPI, plasma
ciproﬂoxacin concentrations peaked rapidly (Figure 2)
and systemic exposure was very low based on day-1
and day-7 AUC and Cmax values (Table III).
The plasma ciproﬂoxacin concentration declined
with a terminal t½ of 3.41 to 5.3 hours after the
ﬁrst dose.
After repeated daily inhalation of ciproﬂoxacin over
7 days, plasma concentrations were similar to those
with single dosing (Figure 2). The Cmax of ciproﬂoxacin
in plasma and the systemic drug exposure (AUC at
steady state) with each dose and frequency were similar
to those recorded with single dosing. The accumulation
ratios for AUC and Cmax in plasma after 7 days of
dosing were close to unity with all 3 ciproﬂoxacin
doses, suggesting an absence of drug accumulation.October 2013Concentrations of ciproﬂoxacin in induced sputum
exhibited substantial interpatient variation (Figure 3).
At 45 minutes after the last dose of ciproﬂoxacin DPI
32.5 mg qd, 65 mg qd, and 32.5 mg bid, the geometric
means (%CV) of induced sputum ciproﬂoxacin
concentrations were 57.7 (118.2), 177.5 (53.4), and
149.7 (249.7) mg/L, respectively. Corresponding values
at 5 hours after the last dose were 2.94 (146.7), 7.80
(96.1), and 24.9 (161.6) mg/L, respectively. There was
no evidence of a relevant increase in ciproﬂoxacin con-
centrations in induced sputum after multiple dosing
compared with the ﬁrst dose (Figure 3). The geometric
mean ratios of induced sputum/plasma concentrations
at 45 minutes and 5 hours after the last doses of
ciproﬂoxacin DPI 32.5 mg qd, 65 mg qd, and 32.5 mg
bid were 1106 and 100, 790 and 69, and 1135 and
375, respectively.
The majority of ciproﬂoxacin was excreted in the
urine, and 3% to 15% of the dose was recovered in
the oral cavity; however, recovery of ciproﬂoxacin
from rinsing ﬂuid concentrations and spontaneous
sputum showed high interpatient variability (data
not shown). The mean concentrations of ciproﬂoxacin
recovered in spontaneous sputum samples were high-
est within the ﬁrst sampling period immediately after
inhalation (0–45 minutes postdose on day 1) (539,
711, and 2023 mg/L with ciproﬂoxacin DPI 32.5 mg
qd, 65 mg qd, and 32.5 mg bid, respectively).
DISCUSSION
In this study, multiple dosing with ciproﬂoxacin DPI
32.5 mg qd, 65 mg qd, or 32.5 mg bid over 7 days
was well tolerated. Most patients experienced at least
1 TEAE; however, these were rated primarily as mild.
An evaluation of lung function was carried out, but
these data were considered biased because of other
interventions performed during the study. In partic-
ular, the measurement of induced sputum, which
increases stress on the lungs, would make lung
function appear decreased compared with what would
be seen in clinical practice after the inhalation of
ciproﬂoxacin DPI. In general, no drug or inhalational
effects on lung function parameters were reported
with ciproﬂoxacin DPI, and there were no obvious
differences in drug-related AEs between the ciproﬂox-
acin DPI dose groups. The most frequent TEAE with
ciproﬂoxacin was “bitter taste” (MedDRA-preferred
term, dysgeusia), which was caused by the known
bitterness of ciproﬂoxacin. Single inhaled doses of1575
Table I. Baseline demographic and clinical characteristics of the population in this study of the tolerability
and pharmacokinetic properties of ciprofloxacin dry powder for inhalation (DPI) 32.5 mg qd, 65 mg
qd, and 32.5 mg bid in patients with cystic fibrosis (safety population, n ¼ 25).
Characteristic
Ciproﬂoxacin DPI
Placebo
(n ¼ 7)
32.5 mg qd
(n ¼ 6)
65 mg qd
(n ¼ 6)
32.5 mg bid
(n ¼ 6)
Age, mean (range), y 31.0 (19.0–40.0) 31.0 (20.0–39.0) 26.8 (19.0–40.0) 27.7 (21.0–39.0)
Sex, no. (%)
Male 3 (50) 3 (50) 0 6 (86)
Female 3 (50) 3 (50) 6 (100) 1 (14)
White ethnicity, no. (%) 6 (100) 6 (100) 6 (100) 7 (100)
Weight, mean (SD), kg 58.3 (10.7) 59.5 (13.1) 63.8 (5.7) 65.4 (6.8)
BMI, mean (SD), kg/m2 19.7 (1.4) 20.1 (2.4) 22.3 (2.4) 21.2 (2.5)
FEV1, mean (range), % predicted 54.2 (32.1–76.7) 57.9 (40.8–78.3) 74.2 (37.8–104.4) 70.0 (42.7–95.2)
BMI ¼ body mass index; FEV1 ¼ forced expiratory volume in 1 second.
Clinical Therapeuticsciproﬂoxacin DPI have been shown previously to be
well tolerated in healthy volunteers and in patients with
CF,18,19 and this study produced no new safety ﬁndings
with multiple dosing in adult patients with CF.Table II. Summary of treatment-emergent adverse eve
pharmacokinetic properties of ciprofloxacin dry
and 32.5 mg bid in patients with cystic fibros
Parameter, no. (%)
32.5 mg q
(n ¼ 6)
Any TEAE 6 (100)
Dysgeusia† 6 (100)
Bronchospasm 4 (67)‡
Cough 2 (33)
Upper respiratory tract infection 1 (17)
Lung infection 1 (17)
Blood creatine phosphokinase increased 1 (17)
Throat irritation 1 (17)
Headache 0
*Patients with multiple events in the same adverse-event catego
†All instances of dysgeusia were termed “bitter taste” (except for
and all were related to study drug in all patients.
‡Related to study drug in 2 patients.
§Related to study drug in 1 patient.
1576The plasma PK properties with single-dose cipro-
ﬂoxacin DPI reported in this study are similar to those
reported in a separate, single-dose study of ciproﬂoxacin
DPI in adult patients with CF.19 In addition, the systemicnts (TEAEs) in this study of the tolerability and
powder for inhalation (DPI) 32.5 mg qd, 65 mg qd,
is (safety population, n ¼ 25).*
Ciproﬂoxacin DPI
Placebo
(n ¼ 7)
d 65 mg qd
(n ¼ 6)
32.5 mg bid
(n ¼ 6)
6 (100) 5 (83) 7 (100)
6 (100) 5 (83) 3 (43)
3 (50) 2 (33)§ 3 (43)§
0 0 1 (14)
1 (17) 1 (17) 0
0 1 (17) 0
0 0 2 (29)
0 0 1 (14)
1 (17) 2 (33)§ 3 (43)
ry were counted only once in that category.
1 instance of “strange powdery taste”) by the investigator,
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Table III. Pharmacokinetic (PK) properties of ciprofloxacin derived from plasmaa and spontaneous sputumb
with single-dose (day 1) and multiple-dose (day 7; steady state) administration of ciprofloxacin dry
powder for inhalation (DPI) 32.5 mg qd, 65 mg qd, and 32.5 mg bid in patients with cystic fibrosis
(PK population, n ¼ 18).
PK Parameter
Ciproﬂoxacin DPI
32.5 mg qd (n ¼ 6)
Ciproﬂoxacin DPI
65 mg qd (n ¼ 6)
Ciproﬂoxacin DPI
32.5 mg bid (n ¼ 6)
Single dose (day 1)
Plasma
AUC12, mg  h/L 0.353 (38.4) 1.24 (33.0) 0.644 (44.8); 0.611 (50.6)c
AUCnorm, kg  h/L 0.705 (36.2) 1.29 (40.8) 1.39 (46.2)
AUC24, mg  h/L 0.386 (37.4) 1.38 (36.1) ND
Cmax, mg/L 0.0896 (33.4) 0.300 (19.6) 0.138 (41.2); 0.0891 (67.5)
c
Cmax, norm, mg/L 0.160 (34.3) 0.271 (10.6) 0.272 (43.9); 0.175 (69.9)
c
Tmax,
d h 0.992 (0.250–2.50) 0.875 (0.250–1.50) 1.25 (0.733–2.00); 2.46 (0.233–3.00)c
t½, h 4.60 (35.3) 5.30 (32.3) 3.41 (25.3); 4.94 (19.5)
c
Sputum
Ae, mg 2.23 (2.04) 2.58 (2.64) 7.55 (7.35)
e; 2.11 (1.88)c,g
Ae, % 6.87 (6.27) 3.98 (4.06) 23.2 (22.6)
e; 5.79 (5.31)c,g
Multiple dose (day 7)
Plasma
AUC12, mg  h/L 0.342 (39.8) 1.30 (35.5) 0.781 (30.9)
AUC24, mg  h/L 0.383 (41.0) 1.47 (37.0) ND
Cmax, mg/L 0.080 (28.6) 0.291 (42.0) 0.151 (26.3); 0.0917 (38.8)
c
Cmax,norm, mg/L 0.143 (30.0) 0.260 (28.3) 0.297 (22.9); 0.181 (39.8)
c
t½, h 5.76 (47.6) 9.49 (30.4) 4.28 (13.2); 7.94 (33.3)
c
Tmax,
d h 1.75 (0.750–2.50) 1.03 (1.00–2.00) 0.883 (0.733–2.03); 2.49 (0.717–3.00)c
Sputum
Ae, mg 2.08 (1.62) 3.75 (3.45) 3.53 (2.38)
e; 6.18 (2.32)f,g
Ae, % 6.41 (4.97) 5.77 (5.31) 10.9 (7.31)
e; 19.0 (7.13)f,g
Accumulation ratio
Rac(Cmax) (day 7/day 1)
d 0.873 (0.672–1.10) 0.994 (0.696–1.51) 1.09 (0.642–1.82)
Rac(AUC) (day 7/day 1)
d 0.955 (0.852–1.27) 1.03 (0.801–1.34) 1.32 (0.831–1.63)
Ae ¼ amount of drug excreted; AUCnorm ¼ dose- and weight-normalized AUC; Cmax,norm ¼ dose- and weight-normalized
Cmax; ND ¼ not determined; Rac ¼ accumulation ratio.
aGeometric mean (% coefﬁcient of variance) unless otherwise speciﬁed.
bArithmetic mean (SD).
cSecond dose.
dMedian (range).
en ¼ 4.
fn ¼ 3.
gn ¼ 2.
H. Stass et al.exposure (indicated by AUC and Cmax values) was low
compared with historical data obtained with intravenous
and oral ciproﬂoxacin (AUC ranging from 4.18 mg  h/LOctober 2013and 5.97 mg  h/L for ciproﬂoxacin 200 mg PO and IV,
respectively, to 15.3 mg  h/L for ciproﬂoxacin 750 mg
PO; Cmax ranging from approximately 1.2 mg/L for1577
0.0001
0.001
0.01
0.1
1
0 8 16 24
C
on
ce
nt
ra
ti
on
 (
m
g/
L)
144 152 160 168 176 184 192
32.5 mg qd
65.0 mg qd
32.5 mg bid
Time (h)
Figure 2. Geometric mean (SD) plasma concentrations with single-dose (day 1) and multiple-dose (day 7;
steady state) administration of ciprofloxacin dry powder for inhalation (DPI) 32.5 mg qd, 65 mg
qd, and 32.5 mg bid in patients with cystic fibrosis (semilogarithmic scale, all subjects valid for
pharmacokinetic analysis who received ciprofloxacin, n ¼ 18).
Clinical Therapeuticsciproﬂoxacin 200 mg PO to approximately 3.0 mg/L for
ciproﬂoxacin 750 mg PO).25,26
A DPI formulation of tobramycin, delivered using
the same device as ciproﬂoxacin DPI, was also well
tolerated in healthy subjects and in patients with
CF.22,27 Radiolabeling showed that a higher percent-
age per inhalation of the administered dose was
delivered to the lungs using the DPI compared with
a nebulizer.22
The PK properties of ciproﬂoxacin DPI were
characterized by rapid pulmonary absorption of
ciproﬂoxacin into the plasma and a relatively short
terminal t½. However, the geometric mean terminal t½
of 9.5 hours on days 1 and 7 was slightly longer than
that previously reported with oral or IV ciproﬂoxacin
(t½, 3.6–7.0 hours).28,29 This longer t½ was also
previously observed in healthy subjects receiving
inhaled ciproﬂoxacin DPI.18 We speculate that these
longer t½ values were due to “ﬂip-ﬂop” kinetics—the
phenomenon of an absorption rate constant that is
lower than the elimination rate constant.30 In this
study, the slow absorption of ciproﬂoxacin DPI from
the lung or slow elimination of the drug from the lung
via physiologic clearance processes (followed by
transfer to the gastrointestinal tract, where it will be
absorbed) could be potentially rate-limiting steps in
the process of drug elimination, and could also be
indicative of lung targeting. Further investigations are
warranted to conﬁrm this interpretation. Slight differ-
ences in the t½ values for days 1 and 7 are attributed
to the fact that, according to the study design, plasma1578concentrations could be measured over a longer
period of time after the last dose, up to 48 hours
postdose. Thus, the data for day 1 reﬂect the domi-
nant t½ during the dosing interval, whereas data for
day 7 reﬂect the terminal phase of the plasma
concentration–time proﬁle.
Multiple once- and twice-daily doses of ciproﬂoxacin
DPI for 7 consecutive days apparently did not result in
accumulation of ciproﬂoxacin in plasma, as was ex-
pected based on the known PK properties of ciproﬂox-
acin administered orally31 or intravenously.28 Systemic
exposure after multiple doses of ciproﬂoxacin DPI was
at least 20-fold less than the exposure observed pre-
viously in healthy volunteers after the administration of
high-dose (750 mg bid) oral ciproﬂoxacin (AUC24,
31.6 mg  h/L)32,33 or high-dose (400 mg tid) intra-
venous ciproﬂoxacin (AUC24, 32.9 mg  h/L).33 These
results support previous ﬁndings that the low systemic
exposure of ciproﬂoxacin DPI in single-dose studies in
healthy subjects18 and in patients with CF19 is
maintained with multiple dosing.
As expected, concentrations of ciproﬂoxacin in
induced sputum were markedly higher than plasma
concentrations, of high variability, and independent of
dose, demonstrating that a high concentration of the
drug was targeted to the lungs. The interpatient
variability in ciproﬂoxacin exposure as measured in
the sputum was consistent with that from a previous
study (data on ﬁle, report no. 12167 [Stass et al.],
Bayer Pharma AG, Wuppertal, Germany)19 and may
reﬂect the technical complexities associated withVolume 35 Number 10
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Figure 3. Individual induced sputum concentrations with single-dose (day 1) and multiple-dose (day 7; steady
state) administration of ciprofloxacin dry powder for inhalation (DPI) 32.5 qd, 65 mg qd, and
32.5 mg bid in patients with cystic fibrosis (semilogarithmic scale, all subjects valid for phar-
macokinetic analysis who received ciprofloxacin, n ¼ 18).
H. Stass et al.sampling induced sputum after induction by
inhalation of nebulized hypertonic saline solution.
Each time an induced sputum sample was taken,
ciproﬂoxacin was cleared from the lungs, thereby
potentially reducing lung exposure to the drug.
There was no evidence of ciproﬂoxacin accumu-
lation in the lungs after multiple dosing over 7 days.
The number of induced sputum samples collected
during this study was limited to minimize potential
AEs associated with the sampling procedure; therefore,
analysis of sputum PK parameters was not planned.
Consequently, the Cmax/minimum inhibitory concen-
tration ratio, an important predictor of antibacterial
efﬁcacy of concentration-dependent ﬂuoroquinolones
such as ciproﬂoxacin,34 could not be determined in
induced sputum. However, in all 3 dose groups, the
ciproﬂoxacin concentration in induced sputum at
45 minutes after the last dose was at least 100-fold
higher than the minimum inhibitory concentration sus-
ceptibility breakpoint for P aeruginosa (Z0.5 mg/L).35
As the drug concentrations declined rapidly thereafter,
the risk for potentially subtherapeutic trough levels
increases with less frequent dosing and cannot be
easily compensated by inhalation of higher doses.
Thus, because an increased frequency of dosing did
not seem to have inﬂuenced tolerability to ciproﬂox-
acin or to have produced drug accumulation, the data
suggest that active lung ciproﬂoxacin concentrations
are best maintained by optimizing the frequency of
dosing.October 2013Study Limitations
A potential limitation of this study was that the
slow absorption of ciproﬂoxacin DPI by the lung and
subsequent absorption by the gastrointestinal tract
were not taken into account. This is currently the
focus of a separate study that our team is conducting,
in which lung deposition is being speciﬁcally studied
using scintigraphy and charcoal block methods in
combination with physiology-based PK modeling.
In this study, total exposure was a composite of drug
reaching the systemic circulation via the gastrointesti-
nal tract and the respiratory tract.
Taken together, these results suggest that ciproﬂox-
acin DPI, at the doses and schedule tested in this study,
is likely to be microbiologically active in patients with
CF. Furthermore, in patients with CF colonized with
pathogens such as P aeruginosa, ciproﬂoxacin DPI
32.5 mg bid is the preferred dose, compared with
32.5 mg qd and 65 mg qd, for delivering effective lung
concentrations while minimizing the risk for systemic
AEs. These conclusions, which are based on PK consi-
derations only, warrant conﬁrmation through clinical
studies that investigate efﬁcacy.
CONCLUSIONS
In this study, ciproﬂoxacin DPI was well tolerated,
achieved high concentrations of ciproﬂoxacin in the
lungs, and was associated with minimal systemic
exposure to, and no apparent accumulation of,1579
Clinical Therapeuticsciproﬂoxacin during a 7-day treatment period. In
addition, the data demonstrate that lung targeting
(ie, low systemic exposure and high drug concentra-
tions at the target) is achieved with ciproﬂoxacin DPI
in patients with CF, particularly compared with
previous data from ciproﬂoxacin administered orally
or intravenously. Although these preliminary data
need to be conﬁrmed in future, larger-scale clinical
trials, these ﬁndings suggest that ciproﬂoxacin DPI
may be a promising candidate for the treatment of
patients with chronic respiratory infections, who often
have complicated and time-consuming treatment regi-
mens.36 The use of ciproﬂoxacin DPI has the potential
to lower the treatment burden time, which may help
to improve adherence and could potentially translate
into better outcomes. The clinical development of
ciproﬂoxacin DPI is ongoing.
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